Sufentanil is a powerful painkiller used to manage severe pain, particularly after surgery or for cancer patients, and it's also used during anesthesia to keep patients comfortable during medical procedures.[2] Sufenta is currently approved and in use across 34 indications[4].[1]
Sufenta is one of 362 small molecule programs targeting Biliary Tract Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
251 competitors in Hepatocellular Carcinoma
Sufenta
Ibrance
Cysteine Hydrochloride
Viread
Sovaldi
Hepsera
Coreg
Doptelet
Miraclid
Vermox
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
May 4, 1984
SUFENTA PRESERVATIVE FREE
NDA NDA019050
Nov 2, 2018
DSUVIA
NDA NDA209128
Sources
Details
Patent Cliff
Jan 5, 2027
Earliest patent expiration — generic entry possible after this date